EUVIMEDEUVIMED entdecken
Crossref

1664-P: Discovery of Selective, Long-Acting Amylin Receptor Agonist for Obesity

SPRING(ZUCHUN) ZHAO, XIAO JIN, GANG CHEN, TAO QIAN, KAI XU, WEIZHONG CHEN, KEKE HU

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1664-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von SPRING(ZUCHUN) ZHAO und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: CH-AM-1 to 3 are potent, long-acting amylin receptor agonists under research for obesity. Unlike some amylin agonist molecules (e.g. Cagrilintide), they are designed to have minimal calcitonin activity.

Methods

Peptides were designed and tested in cAMP assay for activity against AMY1R, AMY3R and selectivity over calcitonin (CTR) receptors, evaluated for body weight reduction in SD or DIO rats and studied for pharmacokinetic (PK) profiles in cynomolgus monkeys. Eloralintide (Lilly), a selective AMY1R agonist in clinical studies, was used as a comparator. Results: cAMP assay EC50 (nM) against AMY1R, selectivity ratios over AMY3R and CTR for CH-AM-1 to 3 vs. eloralintide and Cyno monkey PK result for CH-AM-1 are listed below; CH-AM-1 to 3 generally have higher selectivity than eloralintide against AMY3R and CTR. They also have long T1/2s in monkeys, potentially enabling once monthly dosing in human. Pre-clinical profiling studies of the agonists are on-going.

Conclusion

CH-AM-1 to 3 demonstrated potency against AMY1R, efficacy in rats and PK in cyno monkeys comparable to eloralintide but with enhanced receptors selectivity over AMY3R and CTR. The AMY3R and CTR selectivity is proposed to enable eloralintide having enhanced efficacy and tolerability profiles in clinical trials. Disclosure S. Zhao: None. X. Jin: None. G. Chen: None. T. Qian: None. K. Xu: None. W. Chen: None. K. Hu: None.

Zitieren

APA

ZHAO, S., JIN, X., CHEN, G., QIAN, T., XU, K., CHEN, W., & HU, K. (2026). 1664-P: Discovery of Selective, Long-Acting Amylin Receptor Agonist for Obesity. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1664-p

Vancouver

ZHAO S, JIN X, CHEN G, QIAN T, XU K, CHEN W, et al. 1664-P: Discovery of Selective, Long-Acting Amylin Receptor Agonist for Obesity. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1664-p

BibTeX
@article{ZHAO2026,
  author = {ZHAO, SPRING(ZUCHUN) and JIN, XIAO and CHEN, GANG and QIAN, TAO and XU, KAI and CHEN, WEIZHONG and HU, KEKE},
  title = {1664-P: Discovery of Selective, Long-Acting Amylin Receptor Agonist for Obesity},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1664-p}
}
Kostenlos starten →